Quartz
US · 54 mins ago
Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug
Trutakna, priced at $425,000 per year, is the first drug approved in the U.S. that targets both BAFF and APRIL proteins linked to IgA nephropathy
Do you trust Quartz?
Sign in to rate
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!